BURDEN OF KLEBSIELLA PNEUMONIAE AND ESCHERICHIA COLI ISOLATES THAT PRODUCE EXTENDED-SPECTRUM BETA-LACTAMASES AT THE TERTIARY CARE HOSPITAL IN UTTAR PRADESH, LUCKNOW

NEETI MISHRA; DAYAVANTI KUMARI; KHYATI TIWARI

doi:10.22159/ijpps.2025v17i6.54499

Authors

NEETI MISHRA Department of Microbiology, T. S. Misra Medical College and Hospital Uttar Pradesh, India
DAYAVANTI KUMARI Department of Microbiology, T. S. Misra Medical College and Hospital Uttar Pradesh, India
KHYATI TIWARI Department of Microbiology, T. S. Misra Medical College and Hospital Uttar Pradesh, India

DOI:

https://doi.org/10.22159/ijpps.2025v17i6.54499

Keywords:

Extended-spectrum beta-lactamase, Beta-lactamase

Abstract

Objective: To ascertain the prevalence of Escherichia coli isolates and Klebsiella pneumoniae that generates Extended-Spectrum Beta-Lactamases (ESBLs) in the tertiary care hospital in Lucknow, Uttar Pradesh.

Methods: Screening tests have been developed by the Clinical Laboratory Standard Institute (CLSI) to identify the Klebsiellla pneumoniae and Escherichia coli that generate ESBLs. Finally, performing combination disk test on probable ESBL-producing isolates, ESBL phenotypic confirmation was established.

Results: 94 (62.7%) of the 150 ESBL-positive isolates were female, while 56 (37.3%) were male. The largest concentration of E. coli which was positive for ESBL production was from urine, and it also shows the lowest concentrations coming from sputum, blood, and CSF samples and the largest concentration of ESBL-positive Klebsiella pneumoniae was found in sputum, followed by urine, pus, and blood, while the lowest concentration was found in a CSF sample. E. coli had 158 of the 267 isolates, and of them, 80 were ESBL positive. Similarly, 70 of the 109 Klebsiella pneumoniae isolates tested were ESBL positive.

Conclusion: E. coli had an ESBL prevalence of 53.34% in the current study, while K. pneumoniae had 46.7% prevalence. Klebsiella pneumoniae and Escherichia coli that produce ESBLs were found in relatively high numbers in the urine, sputum, pus, ET aspirate, and blood samples. The doctors must follow stringent infection control procedures at the hospital and judicious antimicrobial usage guidelines.

Downloads

Download data is not yet available.

References

Livermore DM. Bacterial resistance: origins, epidemiology and impact. Clin Infect Dis. 2003 Jan 15;36 Suppl 1:S11-23. doi: 10.1086/344654, PMID 12516026.

Paterson DL, Bonomo RA. Extended spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005 Oct;18(4):657-86. doi: 10.1128/CMR.18.4.657-686.2005, PMID 16223952, PMCID PMC1265908.

Pitout JD, Laupland KB. Extended spectrum beta lactamase producing enterobacteriaceae: an emerging public health concern. Lancet Infect Dis. 2008 Mar;8(3):159-66. doi: 10.1016/S1473-3099(08)70041-0, PMID 18291338.

Steward CD, Wallace D, Hubert SK, Lawton R, Fridkin SK, Gaynes RP. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories. Diagn Microbiol Infect Dis. 2000 Sep;38(1):59-67. doi: 10.1016/s0732-8893(00)00161-9, PMID 11025185.

Gupta V. An update on newer beta lactamases. Indian J Med Res. 2007 Nov;126(5):417-27. PMID 18160745.

Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother. 2007 Feb;59(2):165-74. doi: 10.1093/jac/dkl483, PMID 17158117.

Sturenburg E, Mack D. Extended spectrum beta lactamases: implications for the clinical microbiology laboratory therapy and infection control. J Infect. 2003 Nov;47(4):273-95. doi: 10.1016/s0163-4453(03)00096-3, PMID 14556752.

Perez F, Endimiani A, Hujer KM, Bonomo RA. The continuing challenge of ESBLs. Curr Opin Pharmacol. 2007 Oct;7(5):459-69. doi: 10.1016/j.coph.2007.08.003, PMID 17875405, PMCID PMC2235939.

Romero ED, Padilla TP, Hernandez AH, Grande RP, Vazquez MF, Garcia IG. Prevalence of clinical isolates of escherichia coli and klebsiella spp. producing multiple extended-spectrum beta-lactamases. Diagn Microbiol Infect Dis. 2007 Dec;59(4):433-7. doi: 10.1016/j.diagmicrobio.2007.06.007, PMID 17913435.

Kuo KC, Shen YH, Hwang KP. Clinical implications and risk factors of extended spectrum beta lactamase producing klebsiella pneumoniae infection in children: a case control retrospective study in a medical center in southern Taiwan. J Microbiol Immunol Infect. 2007 Jun;40(3):248-54. PMID 17639166.

Hosoglu S, Gundes S, Kolayli F, Karadenizli A, Demirdag K, Gunaydin M. Extended spectrum beta lactamases in ceftazidime resistant escherichia coli and klebsiella pneumoniae isolates in Turkish hospitals. Indian J Med Microbiol. 2007 Oct;25(4):346-50. doi: 10.4103/0255-0857.37336, PMID 18087082.

Messai Y, Iabadene H, Benhassine T, Alouache S, Tazir M, Gautier V. Prevalence and characterization of extended spectrum β-lactamases in klebsiella pneumoniae in Algiers hospitals (Algeria). Pathol Biol (Paris). 2008;56(5):319-25. doi: 10.1016/j.patbio.2008.05.008, PMID 18585867.

Jacoby GA, Munoz Price LS. The new beta lactamases. N Engl J Med. 2005 Jan 27;352(4):380-91. doi: 10.1056/NEJMra041359, PMID 15673804.

Clinical Laboratory Standards Institute. CLSI performance standards for antimicrobial susceptibility testing. In: proceedings of the 16th international supplement (M100-S16) national committee for clinical laboratory standards, wayne PA USA; 2006.

Murugan N, Malathi J, Therese KL, Madhavan HN. Antimicrobial susceptibility and prevalence of extended spectrum betalactamase (ESBL) and metallo-beta-lactamase (MBL) and its co-existence among pseudomonas aeruginosa recovered from ocular infections. Int J Pharm Pharm Sci. 2015 May 1;7(5):147-51.

National Committee for Clinical Laboratory Standards. NCCLS. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard M7-A5 and informational supplement M100-S10. Wayne PA: National Committee for Clinical Laboratory Standards; 2000.

Shashwati N, Kiran T, Dhanvijay AG. Study of extended spectrum β-lactamase producing enterobacteriaceae and antibiotic coresistance in a tertiary care teaching hospital. J Nat Sci Biol Med. 2014 Jan;5(1):30-5. doi: 10.4103/0976-9668.127280, PMID 24678193, PMCID PMC3961948.

Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum beta lactamase producing gram negative bacteria in a tertiary care hospital. Indian J Med Res. 2002 Apr;115:153-7. PMID 12239838.

Hansotia JB, Agarwal V, Pathak AA, Saoji AM. Extended spectrum beta lactamase-mediated resistance to third-generation cephalosporins in klebsiella pneumoniae in Nagpur central India. Indian J Med Res. 1997 Apr;105:158-61. PMID 9145597.

Lal P, Kapil A, Das BK, Sood S. Occurrence of TEM and SHV gene in extended spectrum beta-lactamases (ESBLs) producing klebsiella sp. isolated from a tertiary care hospital. Indian J Med Res. 2007 Feb;125(2):173-8. PMID 17431288.

Rodrigues C, Joshi P, Jani SH, Alphonse M, Radhakrishnan R, Mehta A. Detection of lactamases in nosocomial gram negative clinical isolates. Indian J Med Microbiol. 2004 Oct-Dec;22(4):247-50. doi: 10.1016/S0255-0857(21)02772-9, PMID 17642748.

Ananthan S, Subha A. Cefoxitin resistance mediated by loss of a porin in clinical strains of klebsiella pneumoniae and escherichia coli. Indian J Med Microbiol. 2005 Jan;23(1):20-3. doi: 10.4103/0255-0857.13867, PMID 15928416.

Gupta S, Maheshwari V. Prevalence of ESBLs among enterobacteriaceae and their antibiotic resistance pattern from various clinical samples. Int J Curr Microbiol App Sci. 2017;6(8):2620-8. doi: 10.20546/ijcmas.2017.609.323.

Mendelson G, Hait V, Ben Israel J, Gronich D, Granot E, Raz R. Prevalence and risk factors of extended spectrum beta lactamase producing escherichia coli and klebsiella pneumoniae in an Israeli long-term care facility. Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):17-22. doi: 10.1007/s10096-004-1264-8, PMID 15660255.

Bazzaz BS, Naderinasab M, Mohamadpoor AH, Farshadzadeh Z, Ahmadi S, Yousefi F. The prevalence of extended-spectrum beta-lactamase-producing escherichia coli and klebsiella pneumoniae among clinical isolates from a general hospital in Iran. Acta Microbiol Immunol Hung. 2009 Mar;56(1):89-99. doi: 10.1556/AMicr.56.2009.1.7, PMID 19388560.

Xiong Z, Zhu D, Zhang Y, Wang F. Extended spectrum beta lactamase in klebsiella pneumoniae and escherichia coli isolates. Zhonghua Yi Xue Za Zhi. 2002 Nov 10;82(21):1476-9. PMID 12509910.

Goossens H, MYSTIC Study Group (Europe). MYSTIC program: summary of European data from 1997 to 2000. Diagn Microbiol Infect Dis. 2001 Dec;41(4):183-9. doi: 10.1016/s0732-8893(01)00320-0, PMID 11777657.

Babypadmini S, Appalaraju B. Extended spectrum lactamases in urinary isolates of escherichia coli and klebsiella pneumonia: prevalence and susceptibility pattern in a tertiary care hospital. Indian J Med Microbiol. 2004 Jul-Sep;22(3):172-4. doi: 10.1016/S0255-0857(21)02830-9, PMID 17642726.